ASX Announcements

27 February 2020

Half Year Report and Accounts

LCT has announced its half yearly report for the six months ended 31 December 2019.

The consolidated loss after tax for the half year amounted to $225,985 (2018 loss: $1,543,294).

Research and development cost were similar to last year due to savings from restructuring now being realised.

This was offset by milestone paym...

30 January 2020

Appendix 4C December Quarter 2019

Living Cell Technologies Limited today released its cash flow report for the quarter ended 31 December 2019. The Appendix 4C is attached. The company ended the quarter with a cash balance of $3,477,874 compared to $3,342,174 in the previous quarter. The cash position was boosted by the sale of 121,995 shares in Semma Therapeutics,...

17 April 2020

Covid-19 Business Impact Update

The global Covid-19 pandemic and the New Zealand Government’s Level 4 restrictions have had an impact on the two projects LCT has underway with the University of Auckland. Due to the closure of the University during the Level 4 restrictions, progress there is currently halted on these two projects which target treatments for obesity and migrai...

29 April 2020

Appendix 4C

LCT ended the March quarter with a cash balance of $3,633,042 compared to $3,477,874 in the previous quarter. The cash balance has been boosted by the R&D rebate from Callaghan Innovation, tax credit from the Inland Revenue Department and reduced expenditure at the University of Auckland because of its closure to contain the spread of COVID-19.<...

8 July 2020

Appendix 3Y - Change of Director's Interest